A recombinant BCG vaccine generates a Th1‐like response and inhibits IgE synthesis in BALB/c mice

Authors:
  • ABA K Behera
    A K Behera
  • HMH Matsuse
    H Matsuse
  • RLR F Lockey
    R F Lockey
  • SMS S Mohapatra
    S S Mohapatra

Abstract
The tubercle vaccine, bacille Calmette–Guérin (BCG), is a strong inducer of T‐helper type 1 (Th1) responsiveness, and it has been suggested that recombinant BCG (rBCG), which produces and secretes antigens, may be used to prevent allergic diseases. The effects of rBCG vaccination on allergic responses in a murine model were examined in this study. A BCG–Escherichia coli shuttle vector was developed with the promoter and signal sequence of the α‐antigen of Mycobacterium bovis, and the vector was tested using E. coliβ‐galactosidase as the model antigen and allergen. This vector enabled the expression of the E. coliβ‐galactosidase gene in BCG, which was detected in its protein extract by immunoblotting analysis. Vaccination of mice with a single dose of 106 recombinant BCG generated a β‐galactosidase‐specific antibody response. The splenocytes of vaccinated mice compared with controls produced significantly higher amounts of interferon‐γ (IFN‐γ) (PPPP<0·01) serum IgE compared with controls. These results together demonstrate that rBCG secreting antigens or allergens may be utilized for the induction of a Th1‐like response and the down‐regulation of IgE antibody response.

This publication has 33 references indexed in Scilit: